Excessive tearing

disease
On this page

Also known as apparatus disease, lacrimalapparatus diseases, lacrimaldisease, lacrimal apparatusdiseases, lacrimal apparatusepiphoralacrimal apparatus disease

Summary

Excessive tearing (MONDO:0001793) is a disease and 28 clinical trials. Top therapeutic interventions include proparacaine, botulinum toxin type a, and nepafenac. A subtype of lacrimal apparatus disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 28

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameexcessive tearing
Mondo IDMONDO:0001793
DOIDDOID:13757
ICD-10-CMH04.2
SNOMED CT193982009
UMLSC0152227
MedGen57518
Is cancer (heuristic)no

Also known as: apparatus disease, lacrimal · apparatus diseases, lacrimal · disease, lacrimal apparatus · diseases, lacrimal apparatus · epiphora · lacrimal apparatus disease

Disease family

This is a subtype of lacrimal apparatus disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital regioneye adnexa disorderlacrimal apparatus disorderexcessive tearing

Related subtypes (16): lacrimal passage granuloma, eversion of lacrimal punctum, stenosis of lacrimal punctum, stenosis of lacrimal passage, primary lacrimal atrophy, secondary lacrimal atrophy, lacrimal system cancer, stenosis of lacrimal sac, acute inflammation of lacrimal passage, chronic inflammation of lacrimal passage, dry eye syndrome, IgG4-related dacryoadenitis and sialadenitis, isolated congenital alacrima, disorder of lacrimal gland, nasolacrimal duct disorder, syndromic lacrimal system disorder

Subtypes (2): epiphora due to insufficient drainage, epiphora due to excess lacrimation

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 28.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified16
PHASE44
PHASE24
PHASE31
PHASE2/PHASE31
PHASE11
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05663684PHASE4RECRUITINGDoes Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?
NCT07372014PHASE4ACTIVE_NOT_RECRUITINGA Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum Stenosis
NCT01010659PHASE4COMPLETEDThe Safety and Efficacy of Lacrimal Silicone Intubation for the Management of Epiphora
NCT04229771PHASE4TERMINATEDDoes Topical Ophthalmic Anesthetic Prior to Probing and Irrigation Decrease Pain?
NCT03436576PHASE3UNKNOWNEfficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye
NCT04637633PHASE2/PHASE3COMPLETEDTopical Cyclosporine-A for Management of Epiphora
NCT00001598PHASE2COMPLETEDDHEA Treatment for Sjogren’s Syndrome
NCT00824811PHASE2WITHDRAWNTopical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel
NCT01282541PHASE2COMPLETEDDetermination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora
NCT03266081PHASE2WITHDRAWNBupivacaine Epiphora Trial
NCT00266838PHASE1COMPLETEDPrevention of Docetaxel Induced Dacryostenosis
NCT02240615EARLY_PHASE1COMPLETEDThe Sinopsys Lacrimal Stent for Lacrimal System Repair in Epiphora
NCT00706251Not specifiedCOMPLETEDFollow up of Nasolacrimal Intubation in Adults
NCT01579344Not specifiedUNKNOWNLacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma
NCT01766232Not specifiedCOMPLETEDLacrimal Drainage Resistance Study
NCT01826734Not specifiedCOMPLETEDAnalysis of 86 Dacryoliths at the University Hospital Ostrava
NCT02386774Not specifiedCOMPLETEDInnovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa
NCT02503956Not specifiedCOMPLETEDPerforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients
NCT02849093Not specifiedUNKNOWNOptical Coherence Tomography of Ocular Structures in Epiphora and Dry Eye Syndrome.
NCT03705000Not specifiedTERMINATEDSLlt Stent II Lacrimal Stent for the Treatment of Nasolacrimal Duct Obstruction
NCT03706443Not specifiedCOMPLETEDTear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops
NCT03731143Not specifiedCOMPLETEDManagement of Lower Punctal Stenosis.
NCT04240431Not specifiedCOMPLETEDLevel of Lacrimal Passage Obstruction
NCT04680078Not specifiedUNKNOWNPlacement of Three Interrupted Sutures After Triangular Three-snip Punctoplasty
NCT04833452Not specifiedUNKNOWNComparative Study Between Wide and Narrow Fenstrum Endoscopic DCR
NCT04968561Not specifiedUNKNOWNDesign of an Augmented Reality System by Integration of CT Scan or MRI Data With Endoscopic Images for Video-assisted Endonasal Endoscopic Surgery
NCT06428266Not specifiedCOMPLETEDClosed Dacryointubation vs Bicanalicular Intubation for Proximal Tear Duct Obstruction
NCT06810089Not specifiedCOMPLETEDExamination of Lacrimal Sac and Nasal Mucosa Preparations Taken in Dacryocystorhinostomy Surgery of Patients With Nasolacrimal Duct Obstruction and Comparison of Clinical Groups With Each Other

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PROPARACAINE42
BOTULINUM TOXIN TYPE A41
NEPAFENAC41
PRASTERONE41
CHEMBL3139901